Citadel Advisors
TRDA icon

Citadel Advisors’s Entrada Therapeutics TRDA Stock Holding History

Citadel Advisors’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,200
Closed -$74.1K – 15122
2025
Q1 		$74.1K Sell
8,200
-400
-5% -$4.98K ﹤0.01% 11848
2024
Q4 		$149K Buy
8,600
+3,800
+79% +$68.8K ﹤0.01% 10897
2024
Q3 		$76.7K Buy
4,800
+4,700
+4,700% +$74.1K ﹤0.01% 11458
2024
Q2 		$1.43K Buy
+100
New +$1.42K ﹤0.01% 13819

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's TRDA Position: Q1 2026 in Review

Citadel Advisors reduced its Entrada Therapeutics (TRDA) stake by 27% in Q1 2026, selling an estimated $891K and leaving 215,018 shares worth $2.71M. The position accounts for ﹤0.01% of the portfolio, ranked #5465.

Citadel Advisors first reported a position in TRDA in Q4 2021 and has held it in 12 quarters since. The position peaked at $3.01M in Q4 2025. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Citadel Advisors held 215,018 shares of Entrada Therapeutics worth $2.71M as of Q1 2026.
  • Citadel Advisors sold 77,752 Entrada Therapeutics shares in Q1 2026, an estimated $891K.
  • Entrada Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5465 holding.
  • Citadel Advisors first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • Citadel Advisors's Entrada Therapeutics position peaked at $3.01M in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.